From HAE UK

It’s been another busy few months for HAE UK, filled with activity, collaboration, and progress for our patient community.

We’ve been working closely with several pharmaceutical companies on a range of patient surveys, making sure patient voices are heard as new treatments and research develop. The feedback continues to shape how HAE care evolves in the UK – so thank you to everyone who has taken part!

In September, HAE UK was proud to attend the 2025 HAEi Regional Conference EMEA in Rome, with just under 50 of our members representing the UK. It was fantastic to connect with patients, clinicians, and organizations from across Europe, the Middle East, and Africa, sharing experiences and learning about the latest developments in HAE care.

Back at home, we’re celebrating the UK approval of garadacimab, a new preventive treatment option for people living with HAE. This marks a big step forward in helping reduce the frequency of attacks and improving HAE patients’ quality of life – and there are even more new therapies on the horizon, which is really exciting.

As always, HAE UK remains dedicated to supporting everyone affected by HAE and ensuring access to the best possible care across the UK.